Pipeline

Overview 2017-05-09T00:55:04+00:00

Therapeutic Area

Drug: Indication (Target)
Preclinical
Phase I
Phase II
Phase III

Anticipated Milestones

Anticipated Milestones

Enroll patients into Phase III AAV study

Initiate clinical endpoint study in aHUS in 2017

Initiate clinical endpoint study in C3G in 1H 2017

Anticipated Milestones

Initiate clinical endpoint study in FSGS in 1H 2017

Vifor Pharma has future development option

Anticipated Milestones

Initiate combination checkpoint inhibitor trial in 2017

Initiate combination checkpoint inhibitor trial in 2017

Drug: Indication (Target)
Pre
PI
PII
PIII
CCX354: Rheumatoid Arthritis/Myeloma Bone Metastasis (CCR1)
Anticipated Milestones

Explore Partnering Options to Advance Program in IBD

CCR1 CCX354 Completed Phase IIa

Progress in TH17 Disease

* also known as CCX168.
** also known as CCX282 or Traficet-EN.